“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry

ConclusionsBetween 34 and 76% of symptomatic patients with HF-REF in a ‘real world’ population are eligible for treatment with sacubitril/valsartan, depending on background ACEI/ARB dose. The most common reason for ineligibility is a low natriuretic peptide level.

http://link.springer.com/10.1007/s10557-019-06873-1

Source: Cardiovascular Drugs and Therapy - March 22, 2019 Category: Cardiology Source Type: research